Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merdarex

Executive Summary

Bispecific monclonal antibody product MDX-240 reduces HIV production in macrophage cultures, according to data presented June 9 in Berlin. MDX-240, composed of two monoclonal antibodies targeting the HIV glycoprotein 41 and the Fc IgG receptor I found on macrophages, was found to neutralize HIV better than anti-gp41 antibody alone. The company plans to file an IND for MDX-240 by the end of the year.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS022788

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel